Previous studies reported that HBV-TCR-T-cell immunotherapy in HBV-HCC patients after liver transplantation with disseminated HCC metastasis in lung, bones and neck or with HCC recurrence had no signs of acute toxicities and only had a largely unremarkable alteration of ALT levels. The gene discussed is GPT; the disease is hepatocellular carcinoma.